Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Charles River Laboratories (CRL)

Charles River to buy Frontage's bioanalysis and DMPK units for $470 million

Neutral Impact 4 of 5 m&a

Charles River Laboratories agreed to acquire the bioanalysis and DMPK operations of Frontage Holdings in Exton, Pennsylvania, for approximately $470 million in cash, plus up to $75 million in performance-based payments. The company expects the deal to be neutral to non-GAAP earnings per share in 2027 and accretive after that, and expects to close in the first half of 2027, subject to shareholder and regulatory approvals.

Key points

  • Purchase price of approximately $470 million in cash, subject to customary closing adjustments, with additional payments of up to $75 million tied to future performance
  • Acquired businesses represented approximately 40% of Frontage's 2025 revenue of $256.7 million and employ approximately 340 people across two Exton sites
  • Expected to be neutral to non-GAAP EPS in 2027 and accretive thereafter; to be financed through Charles River's credit facility and available cash
  • Closing expected in the first half of 2027; Frontage is being taken private by a consortium that includes Tigermed and Dr. Song Li

The filing

CompanyCharles River Laboratories (CRL)
Form8-K, current report
Filed with the SECNov 9, 2026, 6:13 AM ET
Accession number0000950103-26-017127

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 6:18 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.